[16] [17] GLP-1 receptor agonists are not recommended during pregnancy or breastfeeding
doi:10.1016/j.cgh.2024.10.027 37Sharaiha RZ, Kumta NA, Saumoy M, et al
Cch s dng Collagen v Glutathione chng nhn da tn dng ti a tc dng chng nhn da ca Collagen v Glutathione, bn c th s dng sn phm cha c hai cht ny di dng vin ung hoc dng serum dng da
Discover how to manage dryness and discomfort while maintaining vaginal health through simple, effective strategies and affordable care
Everything You Need to Know Before Starting Discover if laser hair removal is worth it with our complete guide, covering benefits, risks, costs, and what to expect before starting treatment
Aleniglipron (Structure Therapeutics) -- Phase 2# Aleniglipron has produced the most competitive oral weight loss data to date: ACCESS: 11.3% placebo-adjusted weight loss at 36 weeks (120 mg) ACCESS II: 15.3% placebo-adjusted weight loss at 36 weeks (240 mg) Low-dose initiation (2.5 mg) significantly improved tolerability Phase 3 planned for mid-2026 At 36 weeks, aleniglipron's trajectory suggests it could approach injectable-level efficacy with longer treatment duration